YOUSSEF MAKKI: Open Payments
NPI 1447825989 · CLARKSTON, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,920 in 83 payments from 17 companies in 2025. Trend: 2023 $1,027 · 2024 $1,453 · 2025 $1,920
Food & beverage: $1,911Education: $9
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $329 |
| Neurocrine BioSciences, Inc. | 9 | $319 |
| ABBVIE INC. | 12 | $311 |
| Otsuka America Pharmaceutical, Inc. | 11 | $212 |
| Lundbeck LLC | 9 | $168 |
| Alkermes, Inc. | 9 | $166 |
| Vanda Pharmaceuticals Inc. | 4 | $96 |
| Supernus Pharmaceuticals, Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 2 | $59 |
| Sage Therapeutics, LLC | 2 | $43 |
Products named: CAPLYTA, INGREZZA, VRAYLAR, REXULTI, ARISTADA, ABILIFY MAINTENA, FANAPT, Qelbree.
Industry payments across MI — which companies pay providers there.
